GLP-1 medications reduce addiction and substance use disorder - VA study

GLP-1 medications suppress appetite by dampening the dopamine-driven reward circuits in the brain that signal hunger. Those same circuits govern cravings for alcohol, nicotine, cocaine, and opioids. A landmark study published in The BMJ in March 2026, examining 606,434 U.S. veterans with type 2 diabetes, found that GLP-1 medications reduced the risk of developing new substance use disorders by 14-25% depending on the substance - and among veterans with existing substance use disorders, GLP-1 use was associated with 50% fewer drug-related deaths and 40% fewer overdoses over a three-year period.

TL;DR

A VA study of 606,434 veterans found GLP-1 medications reduced new substance use disorder risk: 25% for opioids, 20% for cocaine and nicotine, 18% for alcohol, 14% for cannabis. Among veterans with existing substance use disorders, GLP-1 use was associated with 50% fewer drug-related deaths and 40% fewer overdoses. The mechanism appears to be suppression of craving-driven reward circuitry.

What the VA study found

Led by Dr. Ziyad Al-Aly at Washington University School of Medicine and funded by the U.S. Department of Veterans Affairs, the study analysed health records from 524,817 veterans without pre-existing substance use disorders and 81,617 veterans with pre-existing substance use disorders, tracked over up to 3 years.

Prevention of new substance use disorders:

• Opioids: 25% reduced risk (7 fewer cases per 1,000 GLP-1 users)
• Cocaine and nicotine: 20% reduced risk each
• Alcohol: 18% reduced risk
• Cannabis: 14% reduced risk

Harm reduction among veterans with existing substance use disorders:

• Drug-related deaths: 50% reduction
• Overdoses: 40% reduction
• Hospitalisation: 25% reduction
• Emergency department visits: 30% reduction

Notably, the protective effect held across all major classes of addictive substances - the benefit is not substance-specific, suggesting a common mechanism rather than drug-drug interactions.

The mechanism: quieting the craving circuit

Dr. Al-Aly described the mechanism as GLP-1 medications working "against the craving itself." GLP-1 receptors are widely distributed in the brain's reward circuitry - the nucleus accumbens, ventral tegmental area, and other dopaminergic regions that govern motivation and craving across all addictive substances.

When GLP-1 drugs dampen activity in these circuits, they reduce the dopamine surge that makes cravings feel urgent and irresistible. This is the same mechanism that suppresses food cravings - GLP-1 medications reduce the reward-driven motivation to seek food. In people vulnerable to substance use disorders, the same neurobiological quieting appears to reduce the reward-driven motivation to seek drugs or alcohol.

Critically, this is different from traditional addiction treatment medications (naltrexone, methadone, buprenorphine), which block drug effects or manage withdrawal. GLP-1 medications appear to address the upstream craving mechanism itself.

Clinical implications

The VA study does not establish GLP-1 medications as addiction treatment - they are not approved for that indication and were not prescribed for that purpose in the study population. However, the findings open a genuinely novel therapeutic avenue. GLP-1 medications could potentially be part of a multi-modal addiction treatment strategy, targeting the craving circuitry while other interventions address psychological, social, and environmental factors driving substance use.

For people on GLP-1 medications with a personal or family history of substance use disorders, these findings suggest an additional unanticipated benefit of treatment - a potential reduction in relapse risk or new addiction risk.

Supporting recovery on GLP-1 medications

People in recovery from substance use disorders often have nutritional deficiencies from active addiction. Adding GLP-1 medications on top of reduced food intake can compound those gaps. The nutrients most critical for brain health and reward circuit function - B vitamins (especially B6 for neurotransmitter synthesis), magnesium (NMDA receptor regulation), and zinc (dopamine metabolism) - are exactly those most depleted in GLP-1 users. GLP-1 Shield is formulated around these specific gaps.

Frequently asked questions

Can Ozempic or Wegovy treat addiction?

No - GLP-1 medications are not approved for addiction treatment. However, a VA study found GLP-1 use was associated with reduced substance use disorder risk and fewer drug-related deaths in veterans with existing substance use disorders. This is an unanticipated benefit signal, not an indication for treatment.

How do GLP-1 medications reduce addiction risk?

GLP-1 receptors are distributed widely in the brain's reward circuitry. The medications appear to dampen dopamine-driven craving mechanisms across multiple addictive substances - a common mechanism rather than drug-specific interactions.

If I have a history of substance use, should I take a GLP-1 medication?

The VA study suggests GLP-1 medications may provide additional benefit for people with substance use disorder history, but they are not a treatment. If you are considering a GLP-1 medication, discuss your substance use history explicitly with your prescriber - it may actually be a reason to use the medication, not a reason to avoid it.

What about people in active addiction or early recovery?

The study does not provide data on actively addicted populations. For people in early recovery (first months after detoxification), coordinating GLP-1 initiation with addiction treatment specialists is important to ensure the medication complements, not complicates, recovery support.